A Multi-center, Randomized, Double-blind, Placebo-controlled Phase I/II Trial to Compare the Safety, Tolerability and Immunogenicity of the Therapeutic THV01 Vaccination at 5.10E+6 TU (Transducing Unit) , 5.10E+7 TU (Transducing Unit) or 5.10E+8 TU (Transducing Unit) Doses to Placebo in HIV-1 Clade B Infected Patients Under Highly Active Antiretroviral Therapy (HAART)
Phase of Trial: Phase I/II
Latest Information Update: 20 May 2019
At a glance
- Drugs THV 01 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; First in man
- Sponsors THERAVECTYS
- 10 Apr 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 08 Dec 2015 Planned end date changed from 1 Nov 2015 to 1 Mar 2019, as reported by ClinicalTrials.gov.